Form 4: Sutro Biopharma Director Michael Dybbs Reports Stock Option Grant

Director Michael Dybbs reports the acquisition of stock options in Sutro Biopharma, Inc.

Summary

• Michael Dybbs, a director of Sutro Biopharma, Inc., filed a Form 4 to report changes in beneficial ownership.
• On June 6, 2024, Dybbs acquired stock options to purchase 35,000 shares of Sutro Biopharma's common stock at an exercise price of $3.76.
• The options vest monthly starting July 6, 2024, with full vesting by the earlier of the 2025 annual stockholders meeting or June 6, 2025, contingent on continued service.

Sentiment

Score: 7

Explanation: The sentiment is neutral to positive as it reflects a standard compensation practice that aligns director interests with shareholder value. There are no indications of negative news or concerns.

Positives

• The grant of stock options aligns the director's interests with those of the shareholders, incentivizing him to work towards the company's success.

Future Outlook

The director's continued service is required for the options to fully vest.

Industry Context

Stock option grants are a common form of executive compensation in the biotechnology industry, aligning management's interests with shareholder value creation.

Comparison to Industry Standards

• Stock option grants to directors are a standard practice in publicly traded companies, particularly in the biotech sector.
• The vesting schedule of monthly vesting over a year is fairly typical.
• Comparable companies such as Amgen, Gilead, and Biogen also utilize stock options as part of their director compensation packages.

Stakeholder Impact

• Shareholders may view the stock option grant positively as it incentivizes the director to work towards increasing shareholder value.
• The director is incentivized to remain with the company to ensure full vesting of the options.

Key Dates